LIGAND PHARM Performance

LGNZZ -- USA Stock  

USD 0.12  0.001  0.83%

LIGAND PHARM holds performance score of 10 on a scale of zero to a hundred. The company secures Beta (Market Risk) of -0.2066 which conveys that as returns on market increase, returns on owning LIGAND PHARM are expected to decrease at a much smaller rate. During bear market, LIGAND PHARM is likely to outperform the market.. Although it is vital to follow to LIGAND PHARM INC price patterns, it is good to be conservative about what you can actually do with the information regarding equity historical price patterns. Macroaxis philosophy towards estimating future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if LIGAND PHARM expected return of 1.2199 will be sustainable into the future, we have found twenty-one different technical indicators which can help you to check if the expected returns are sustainable. Use LIGAND PHARM INC Standard Deviation, Value At Risk, Kurtosis, as well as the relationship between Jensen Alpha and Semi Variance to analyze future returns on LIGAND PHARM INC.
Horizon     30 Days    Login   to change

LIGAND PHARM INC Relative Risk vs. Return Landscape

If you would invest  8.20  in LIGAND PHARM INC on November 15, 2018 and sell it today you would earn a total of  3.80  from holding LIGAND PHARM INC or generate 46.34% return on investment over 30 days. LIGAND PHARM INC is currently producing 1.2199% returns and takes up 8.0249% volatility of returns over 30 trading days. Put another way, 72% of traded equities are less volatile than the company and 77% of traded equity instruments are likely to generate higher returns over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, LIGAND PHARM INC is expected to generate 6.29 times more return on investment than the market. However, the company is 6.29 times more volatile than its market benchmark. It trades about 0.15 of its potential returns per unit of risk. The DOW is currently generating roughly -0.11 per unit of risk.

LIGAND PHARM Market Risk Analysis

Sharpe Ratio = 0.152
Good Returns
Average Returns
Small ReturnsLGNZZ
Negative Returns

LIGAND PHARM Relative Performance Indicators

Estimated Market Risk
  actual daily
 72 %
of total potential
Expected Return
  actual daily
 23 %
of total potential
Risk-Adjusted Return
  actual daily
 10 %
of total potential
Based on monthly moving average LIGAND PHARM is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LIGAND PHARM by adding it to a well-diversified portfolio.

LIGAND PHARM Performance Rating

LIGAND PHARM INC Risk Adjusted Performance Analysis


Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in LIGAND PHARM INC are ranked lower than 10 (%) of all global equities and portfolios over the last 30 days.


Equity Alerts and Improvement Suggestions

LIGAND PHARM INC appears to be very risky and stock price may revert if volatility continues
LIGAND PHARM INC has some characteristics of a very speculative penny stock
Latest headline from Arrowhead Pharmaceuticals, Inc. CEO Christopher Anzalone on Q4 2018 Results - Earnings Call Transcript - Seeking Alpha

LIGAND PHARM Performance Indicators

LIGAND PHARM INC Basic Price Performance Measures

Fifty Two Week High0.14
Please see also Stocks Correlation. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.